UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdic ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2019 Earnings Conference Call November 7, 2019 8:00 AM ET Company Participants John Craighead – Vice President-Investor Relations and Corporate Communications Pascal Touchon – President and Chief Executive Officer AJ Joshi – Chief Medical Officer Conference Call Participants Anupam Rama – JPMorgan John Newman – Canaccord Salim Syed – Mizuho Securities Phil Nadeau – Cowen and Company Tony Butler – Roth Capital Salveen Richter – Goldman Sachs Ben Burnett – Stifel M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdicti ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q2 2019 Results Earnings Conference Call August 8, 2018 8:00 AM ET Company Participants John Craighead - Vice President of Investor Relations and Corporate Communications Pascal Touchon - President and Chief Executive Officer AJ Joshi - Chief Medical Officer Chris Haqq - Chief Scientific Officer Conference Call Participants Anupam Rama - JP Morgan John Newman - Canaccord Genuity Salim Syed - Mizohu Americas Matt Phipps - William Blair Philip Nadeau - Cowen and C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdiction of ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants John Craighead - Vice President of Investor Relations and Corporate Communications Isaac Ciechanover - President and Chief Executive Officer Dietmar Berger - Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan John Newman - Canaccord Salim Syed - Mizuho Matt Phipps - William Blair Maryana Breitman - Goldman Sac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 | --- | --- | |------------------------------------------------------------------------------|--------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36548 | --- | --- | |-------------------------------------------------------------------------------------------------|-------------- ...